Author

E. Brenner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Organism:human· 2 Assay:scRNA-seq· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Brock· 2 shared K. E. Johnson· 2 shared A. Al'Khafaji· 1 shared A. L. Gardner· 1 shared A. M. Al'Khafaji· 1 shared A. M. Jarrett· 1 shared C. Gutierrez· 1 shared C. J. Wu· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Brock

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrating multimodal data sets into a mathematical framework to describe and predict therapeutic resistance in cancer

K. E. Johnson, G. R. Howard, D. Morgan, E. Brenner, A. L. Gardner, R. E. Durrett, W. Mo, A. M. Al'Khafaji, E. Sontag, A. M. Jarrett, T. E. Yankeelov, A. Brock

This paper develops a framework integrating single-cell transcriptomic data with longitudinal treatment response data to predict drug resistance in breast cancer, achieving higher predictive accuracy with integrated data.

bioRxiv · Feb 11, 2020Cancer Biology

Expressed barcodes enable clonal characterization of chemotherapeutic responses in chronic lymphocytic leukemia

A. Al'Khafaji, C. Gutierrez, E. Brenner, R. Durrett, K. E. Johnson, W. Zhang, S. Li, K. J. Livak, D. Neuberg, A. Brock, C. J. Wu

This paper develops a method to study clonal responses to chemotherapy in CLL by combining barcoding with single-cell RNA sequencing, revealing that rare drug-tolerant clones dominate post-treatment populations.

bioRxiv · Sep 8, 2019Cancer Biology